ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
FDA Approves Ripretinib for Advanced Gastrointestinal Stromal Tumor americanpharmaceuticalreview
May 28, 2020The Food and Drug Administration (FDA) approved ripretinib (QINLOCK, Deciphera Pharmaceuticals), for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Pharma Sources Insight January 2025
